Fig. 4

Drug- and gene-mediated interactions. This figure shows the total number (%) of interactions identified (a), the number (%) of interactions per patient (b), and the percentage of interactions mediated per enzyme/transporter (c) in 652 post-NSTE-ACS patients. The pie charts on the left display all interactions (of any or unconfirmed strength), whilst predicted substantial interactions only are presented in the charts on the right. In a and b, each interaction was counted only once. In c, some types of interaction were counted more than once in a given patient. These were as follows: DDIs where a perpetrator drug can influence the same victim drug through more than one enzyme/transporter (e.g. verapamil inhibiting atorvastatin at both CYP3A4/5 and P-gp), DDGIs involving more than one enzyme/transporter, and DGGIs. These interactions were included in the count of both involved enzymes/transporters to illustrate them clearly in c only